<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ENLON PLUS- edrophonium chloride and atropine sulfate injection, solution </strong><br>Mylan Institutional LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1fc6e59c-c96c-4fa0-b6cc-b41065553715"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_b7b297d5-6dfb-4ddc-850e-d6ad0f7dc2f7"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection, for intravenous use, is a sterile, nonpyrogenic, nondepolarizing neuromuscular relaxant antagonist. ENLON-PLUS is a combination drug containing a rapid acting acetylcholinesterase inhibitor, edrophonium chloride, and an anticholinergic, atropine sulfate. Chemically, edrophonium chloride is ethyl (m-hydroxyphenyl) dimethylammonium chloride; its structural formula is:</p>
<div class="Figure">
<a name="id254"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=358336e5-3628-49ec-9134-6ec8c4ea733a&amp;name=91173b67-b234-4b01-8598-5e14b8ef2fe4-01.jpg">
</div>
<p>Molecular Formula: C<span class="Sub">10</span>H<span class="Sub">16</span>ClNO</p>
<p>Molecular Weight: 201.70</p>
<p>Chemically, atropine sulfate is: endo-(±)-alpha-(hydroxymethyl)-8-methyl-8-azabicyclo [3.2.1]oct-3-yl benzeneacetate sulfate (2:1) monohydrate. Its structural formula is:</p>
<div class="Figure">
<a name="id260"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=358336e5-3628-49ec-9134-6ec8c4ea733a&amp;name=91173b67-b234-4b01-8598-5e14b8ef2fe4-02.jpg">
</div>
<p>Molecular Formula: (C<span class="Sub">17</span>H<span class="Sub">23</span>NO<span class="Sub">3</span>)<span class="Sub">2</span>•H<span class="Sub">2</span>SO<span class="Sub">4</span>•H<span class="Sub">2</span>O</p>
<p>Molecular Weight: 694.84</p>
<p>ENLON-PLUS contains in each mL of sterile solution:</p>
<p><span class="Bold">5 mL Ampule: </span>10 mg edrophonium chloride and 0.14 mg atropine sulfate compounded with 2.0 mg sodium sulfite as a preservative and buffered with sodium citrate and citric acid. The pH range is 4.0-5.0.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_add44c54-ef80-4cd2-8421-5f6c8bd168cf"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_24416fd5-5a10-42c1-b25a-541eb0dcdee4"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection is a combination of an anticholinesterase agent, which antagonizes the action of nondepolarizing neuromuscular blocking drugs, and a parasympatholytic (anticholinergic) drug, which prevents the <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">muscarinic effects</span> caused by inhibition of acetylcholine breakdown by the anticholinesterase. Edrophonium chloride antagonizes the effect of nondepolarizing neuromuscular blocking agents primarily by inhibiting or inactivating acetylcholinesterase. By inactivating the acetylcholinesterase enzyme, acetylcholine is not hydrolyzed as rapidly by acetylcholinesterase and is thereby allowed to accumulate. The greater quantity of acetylcholine reaching the sites of nicotinic cholinergic postjunctional receptors improves transmission of impulses across the myoneural junction. The concomitant, unavoidable accumulation of acetylcholine at the sites of muscarinic cholinergic transmission occurring at the parasympathetic, postganglionic receptors of the autonomic nervous system, may cause <span class="Bold"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span>, increased secretions, </span>and other parasympathomimetic side effects. The magnitude of these muscarinic side effects can be expected to vary from patient to patient depending upon the amount of vagal nerve activity present. Atropine sulfate counteracts these side effects.</p>
<p>Intravenous edrophonium chloride in doses of 0.5 to 1.0 mg/kg promptly antagonizes the effects of nondepolarizing muscle relaxants reaching the maximum antagonism within 1.2 minutes. A plateau of maximal antagonism is sustained for 70 minutes<span class="Sup">1</span>. Intravenous atropine sulfate has an immediate effect on heart rate which reaches a peak in 2 to 16 minutes and lasts 170 minutes after an average 0.02 mg/kg dose.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_976ac0bc-dc0e-464a-bf14-581542c3b8e9"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5437d49-12c1-46c6-a7c2-4fe1db8fe339"></a><a name="section-3.2.1"></a><p></p>
<h3>EDROPHONIUM CHLORIDE</h3>
<p class="First">Edrophonium chloride given intravenously shows first order elimination in a two compartment open pharmacokinetic model<span class="Sup">3</span>. Onset of reversal of muscle relaxant induced <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in twitch <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> occurs within three minutes. Edrophonium is primarily renally excreted with 67% of the dose appearing in the urine<span class="Sup">4</span>. Hepatic metabolism and biliary excretion have also been demonstrated in animals<span class="Sup">4,8</span>. While infants and children have been shown to have a reduced plasma half-life and an increased clearance of edrophonium, doses in children are not significantly different from adults on a mg/kg basis although they are more variable in effect. Conversely, elderly subjects (&gt;75 years old) have a prolonged plasma half-life and a reduced clearance. Studies have shown that in spite of these changes the onset and duration of action is unchanged in these patients.</p>
<a name="_Refid_e97f7078-102d-4a2d-843a-61f7adc08"></a><table>
<caption><span>Table of Pharmacokinetic Values for Edrophonium Chloride</span></caption>
<col width="24%">
<col width="10%">
<col width="13%">
<col width="19%">
<col width="5%">
<col width="6%">
<thead><tr class="First Last">
<th class="Botrule Toprule" valign="top"><span class="Bold">Population</span></th>
<th class="Botrule Toprule" valign="top">
<span class="Bold">T1/2β</span><br><span class="Bold">hr±S.D.</span>
</th>
<th class="Botrule Toprule" valign="top">
<span class="Bold">VD</span><br><span class="Bold"> L/kg±S.D.</span>
</th>
<th class="Botrule Toprule" valign="top">
<span class="Bold">Cl</span><br><span class="Bold"> mL/kg/min±S.D.</span>
</th>
<th class="Botrule Toprule" valign="top"><span class="Bold">N</span></th>
<th class="Botrule Toprule" valign="top"><span class="Bold">Ref.</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="6" valign="top">T1/2β = Elimination half-life</td></tr>
<tr><td class="Botrule" align="left" colspan="6" valign="top">VD = Volume of distribution</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="6" valign="top">Cl = Clearance</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>No adjustments of edrophonium dosage are required because elimination of non-depolarizing muscle relaxants is similarly decreased.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Values for anephric patients were calculated using a non-compartmental model.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>From a study using a different, less sensitive HPLC method and fitting C vs T data to a biexponential curve.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">Adults</p></td>
<td class="Toprule" align="center"><p class="First">1.8±0.6</p></td>
<td class="Toprule" align="center"><p class="First">1.1±0.2</p></td>
<td class="Toprule" align="center"><p class="First">9.6±2.7</p></td>
<td class="Toprule" align="center"><p class="First">10</p></td>
<td class="Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">Anephric Patients<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td align="center"><p class="First">3.4±1.0</p></td>
<td align="center"><p class="First">0.68±0.13</p></td>
<td align="center"><p class="First">2.7±1.4</p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First">Infants (3 wks-11 mos)</p></td>
<td align="center"><p class="First">1.2±0.5</p></td>
<td align="center"><p class="First">1.2±0.2</p></td>
<td align="center"><p class="First">17.8±1.2</p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">Children (1-6 yr)</p></td>
<td align="center"><p class="First">1.6±0.5</p></td>
<td align="center"><p class="First">1.2±0.7</p></td>
<td align="center"><p class="First">14.2±7.3</p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">Adults</p></td>
<td align="center"><p class="First"><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>0.9±0.3</p></td>
<td align="center"><p class="First">1.1±0.6</p></td>
<td align="center"><p class="First">13.3±5</p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">6</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Elderly<a href="#footnote-1" class="Sup">*</a> (over 75 yr)</p></td>
<td class="Botrule" align="center"><p class="First"><a href="#footnote-3" class="Sup">‡</a>1.4±0.3</p></td>
<td class="Botrule" align="center"><p class="First">0.6±0.1</p></td>
<td class="Botrule" align="center"><p class="First">5.1±1</p></td>
<td class="Botrule" align="center"><p class="First">5</p></td>
<td class="Botrule" align="center"><p class="First">6</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5f6df493-376d-4ece-a6a3-8d9429cc3934"></a><a name="section-3.2.2"></a><p></p>
<h3>ATROPINE SULFATE</h3>
<p class="First">Atropine sulfate given intravenously shows first order elimination in a two compartment open model<span class="Sup">7</span>. Approximately 57% of a dose of atropine appears in the urine as unchanged drug. Tropine is the primary hepatic metabolite of atropine and it accounts for approximately 30% of the dose<span class="Sup">2</span>. Atropine is only 14±9% bound to plasma proteins<span class="Sup">7</span>. Atropine clearance in children under 2 years old and in the elderly is decreased in relation to normal healthy adults.</p>
<a name="_Refid_23adc25d-6409-4358-bf2d-c3ce56283"></a><table>
<caption><span>Table of Pharmacokinetic Values for Atropine Sulfate</span></caption>
<col width="23%">
<col width="10%">
<col width="13%">
<col width="19%">
<col width="5%">
<col width="6%">
<thead><tr class="First Last">
<th class="Botrule Toprule" valign="top"><span class="Bold">Population</span></th>
<th class="Botrule Toprule" valign="top">
<span class="Bold">T1/2β</span><br><span class="Bold">hr±S.D.</span>
</th>
<th class="Botrule Toprule" valign="top">
<span class="Bold">VD</span><br><span class="Bold"> L/kg±S.D.</span>
</th>
<th class="Botrule Toprule" valign="top">
<span class="Bold">Cl</span><br><span class="Bold"> mL/kg/min±S.D.</span>
</th>
<th class="Botrule Toprule" valign="top"><span class="Bold">N</span></th>
<th class="Botrule Toprule" valign="top"><span class="Bold">Ref.</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="6" valign="top">T1/2β = Elimination half-life</td></tr>
<tr><td class="Botrule" align="left" colspan="6" valign="top">VD = Volume of distribution</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="6" valign="top">Cl = Clearance</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>No dose adjustment required because the cardiovascular effect of atropine is diminished in the elderly.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">Adults</p></td>
<td class="Toprule" align="center"><p class="First">3.0±0.9</p></td>
<td class="Toprule" align="center"><p class="First">1.6±0.4</p></td>
<td class="Toprule" align="center"><p class="First">6.8±2.9</p></td>
<td class="Toprule" align="center"><p class="First">8</p></td>
<td class="Toprule" align="center"><p class="First">7</p></td>
</tr>
<tr>
<td><p class="First">Children (0.08-10 yrs)</p></td>
<td align="center"><p class="First">4.8±3.5</p></td>
<td align="center"><p class="First">2.2±1.5</p></td>
<td align="center"><p class="First">6.4±3.9</p></td>
<td align="center"><p class="First">13</p></td>
<td align="center"><p class="First">7</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Elderly<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a> (65-75 yrs)</p></td>
<td class="Botrule" align="center"><p class="First">10.0±7.3</p></td>
<td class="Botrule" align="center"><p class="First">1.8±1.2</p></td>
<td class="Botrule" align="center"><p class="First">2.9±1.9</p></td>
<td class="Botrule" align="center"><p class="First">10</p></td>
<td class="Botrule" align="center"><p class="First">7</p></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_0c68897d-f965-4138-a931-f3fcb26448a6"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection is recommended as a reversal agent or antagonist of nondepolarizing neuromuscular blocking agents. It is not effective against depolarizing neuromuscular blocking agents. It is also useful if used adjunctively in the treatment of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> caused by curare overdosage. </p>
<p>The appropriateness of the specific fixed ratio of edrophonium and atropine contained in ENLON-PLUS has not been evaluated in <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Therefore, ENLON-PLUS is not recommended for use in the differential diagnosis of this condition.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_d63450a4-8a7c-4b6c-bc8d-a0437f888ebf"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection is not to be used in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to either of the components, or in patients with intestinal or urinary obstruction of mechanical type. Atropine sulfate is contraindicated in the presence of <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">acute glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesions</span> (synechiae) between the iris and lens of the eye, and <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_258448ed-a466-4181-826f-8929871c1a10"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection should be used with caution in patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> has been reported to occur in digitalized patients as well as in jaundiced subjects receiving <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors. In patients with cardiovascular disease, given anesthesia with narcotic and nitrous oxide without a potent inhalational agent, there is increased risk for clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. In patients receiving beta-adrenergic blocking agents there is increased risk for excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> from unopposed parasympathetic vagal tone. Such patients should receive atropine sulfate alone prior to ENLON-PLUS. Isolated instances of <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> have also been reported following the administration of edrophonium chloride. Additional atropine sulfate (1 mg) should be available for immediate use to counteract severe cholinergic reaction which may occur in hypersensitive individuals when ENLON-PLUS is used.</p>
<p>ENLON-PLUS contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people. </p>
<p>There is a potential for tissue irritation by extravascular injection.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_bda72486-5569-41f7-8782-35a9b174d1bd"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_f7afb4a8-cf4d-4028-bed8-b710e107279e"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">As with any antagonist of nondepolarizing muscle relaxants, adequate recovery of voluntary respiration and neuromuscular transmission must be obtained prior to the discontinuation of respiratory assistance. Should a patient develop "anticholinesterase insensitivity" for brief or <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, the patient should be carefully monitored and the dosage of anticholinesterase drugs reduced or withheld until the patient again becomes sensitive to them. Use with caution in patients with <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and in debilitated patients with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>.</p>
<p>When used in therapeutic doses, atropine can cause dryness of the mouth. This effect is additive when the product is administered with other drugs that can cause dryness of the mouth.</p>
<p>Since atropine sulfate slows gastric emptying and gastrointestinal motility, it may interfere with the absorption of other medications. The effect of atropine on dryness of the mouth may be increased if it is given with other drugs that have anticholinergic action (tricyclic antidepressants, antipsychotics, some antihistamines, and antiparkinsonism drugs). </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_61b7d12a-005d-4143-82f4-ec4c6aed1c59"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection should not be administered prior to the administration of any nondepolarizing muscle relaxants. It should be administered with caution to patients with symptoms of myasthenic <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> who are also on anticholinesterase drugs. Anticholinesterase overdosage (<span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>) symptoms may mimic underdosage (myasthenic <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>), so the use of this drug may worsen the condition of these patients (see <span class="Bold"><a href="#i4i_overdosage_id_overdosage">OVERDOSAGE </a></span>section for treatment).</p>
<p>Narcotic analgesics, except when combined with potent inhaled anesthetics, appear to potentiate the effect of edrophonium on the sinus node and conduction system, increasing both the frequency and duration of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. In patients with cardiovascular disease, given anesthesia with narcotic and nitrous oxide without a potent inhalational agent, there is increased risk for clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. In patients receiving beta-adrenergic blocking agents there is increased risk for excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> from unopposed parasympathetic vagal tone. Such patients should receive atropine sulfate alone prior to ENLON-PLUS.</p>
<p>Compared to muscle relaxants with some vagolytic activity, muscle relaxants with no vagolytic effects, i.e. vecuronium, may be associated with a slightly higher incidence of vagotonic effects such as <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and first-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> when reversed with ENLON-PLUS.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_5d14ce2b-a987-48e5-8a5a-0f7777f5244e"></a><a name="section-7.3"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">Animal reproduction studies have not been conducted with ENLON-PLUS. It is also not known whether ENLON-PLUS can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ENLON-PLUS should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_5b864a25-0762-4fdb-b4a3-fb4367a006c3"></a><a name="section-7.4"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The effect of ENLON-PLUS on the mother and fetus, on the duration of labor or delivery, in the possibility that a forceps delivery or other intervention or resuscitation of the newborn will be necessary, is not known. The effect of the combination drug on the later growth, development and functional maturation of the child is also unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_654b4bed-5ec7-4b6b-8d90-454ec0264513"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">The safety of ENLON-PLUS during lactation in humans has not been established.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_97f64eb9-086d-475c-b435-3d544270c448"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. Pediatric patients may have increased vagal tone. The effect of fixed ratios of edrophonium and atropine on heart rate in such patients has not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_a5837a8b-1ed1-435c-a9b0-9bd9dfbc7fad"></a><a name="section-7.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of ENLON-PLUS did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_7a1a6a56-69b1-470d-afea-3be45d170c51"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_70c307d4-ae15-40fb-be80-8d3fdb460b68"></a><a name="section-8.1"></a><p></p>
<p class="First"><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> Frequency &gt;10%: <span class="product-label-link" type="condition" conceptid="4038688" conceptname="AV junctional rhythm">junctional rhythm</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; Frequency 3-10%: first and second degree A-V block, P Wave changes, atrial premature contractions; Frequency 1-3%: third degree A-V block, ventricular premature contractions; Frequency less than 1%: 3 second R-R interval.</p>
<p>Of the patients who experienced any <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, 85% had the onset within two minutes, 74% no longer had any <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> after 10 minutes. <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> related to increased vagal tone, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, second and third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> respond to treatment with 0.2-0.4 mg of atropine I.V. (<span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">Bigeminy</span> or ventricular ectopy may be treated with lidocaine 50 mg I.V.). </p>
<p>Adverse experiences reported for anticholinesterase agents such as edrophonium chloride, but not observed in the 235 patients studied with ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection:</p>
<p><span class="Bold">Cardiovascular: </span>Nonspecific EKG changes, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> leading to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; </p>
<p><span class="Bold">Respiratory: </span>Increased tracheobronchial secretions, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, bronchiolar constriction and respiratory muscle <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>;</p>
<p><span class="Bold">Neurologic: </span><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, and <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>;</p>
<p><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, increased peristalsis, increased gastric and intestinal secretions, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>;</p>
<p><span class="Bold">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span> and <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculations</span>;</p>
<p><span class="Bold">Miscellaneous: </span><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Increased urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, increased <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, pupillary constriction, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, and <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>.</p>
<p>Untoward reactions to atropine sulfate generally are dose-related. Individual tolerance varies greatly but systemic doses of 0.5 to 10 mg are likely to produce the following effects, which were not observed in the 235 patients treated with ENLON-PLUS: </p>
<p>NEUROLOGIC: Speech disturbances and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> with <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>; </p>
<p>DERMATOLOGIC: <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushed</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, formation of a scarlatiniform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; </p>
<p>MISCELLANEOUS: Dryness of the nose and mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, slight <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. Atropine may produce <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> through inhibition of heat loss by evaporation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_overdosage"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Muscarinic symptoms (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, increased bronchial and salivary secretions and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>) may appear with overdosage (<span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>) of ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection, but may be managed by the use of additional atropine sulfate. Obstruction of the airway by bronchial secretions can arise and may be managed with suction (especially if tracheostomy has been performed).</p>
<p>Should edrophonium chloride overdosage occur:</p>
<dl>
<dt>1.</dt>
<dd>Maintain respiratory exchange.</dd>
<dt>2.</dt>
<dd>Monitor cardiac function. </dd>
</dl>
<p>Appropriate measures should be taken if <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> occur or <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> is present. </p>
<p>Principal manifestations of overdosage (<span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>) with atropine sulfate are <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. In the treatment of atropine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, respiratory assistance and symptomatic support are indicated. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> is usually due to <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the medullary centers.</p>
<p>In the clinical studies performed with ENLON-PLUS, there were no reported <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> and therefore no clinical information is available regarding overdosing with ENLON-PLUS.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_069657fd-d87f-42fb-aca5-34ff69f4b1a0"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosages of ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection range from 0.05-0.1 mL/kg given slowly over 45 seconds to 1 minute at a point of at least 5% recovery of twitch response to neuromuscular stimulation (95% block). The dosage delivered is 0.5-1.0 mg/kg of edrophonium chloride and 0.007-0.014 mg/kg of atropine sulfate. A total dosage of 1.0 mg/kg of edrophonium chloride should rarely be exceeded. Response should be monitored carefully and assisted or controlled ventilation secured. Satisfactory reversal permits adequate voluntary respiration and neuromuscular transmission (as tested with a peripheral nerve stimulator). Recurarization has not been reported after satisfactory reversal has been attained.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_f975cd0d-025e-4c68-a6fa-6753ed23140c"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection should be stored at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<table>
<col width="21%">
<col width="38%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First">NDC 67457-192-05 </p></td>
<td class="Toprule"><p class="First">5 mL Single-Dose Ampule, Box of 10</p></td>
</tr>
<tr class="Last">
<td class="Botrule"></td>
<td class="Botrule"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_7562b3c3-84a7-4ed6-8cd3-e8afdc030b26"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold">Cronnelly R, Morris RB, Miller RD: </span>Edrophonium: Duration of action and atropine requirement in humans during halothane anesthesia. Anesthesiology 1982;57:261-266.</dd>
<dt>2.</dt>
<dd>
<span class="Bold">Hinderling PH, Gundert-Remy U, Schmidlin O, Heinzel G: </span>Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. I: Pharmacokinetics; II: Pharmacodynamics. J Pharmaceutical Sci 1985; 74:I-703-710; II-711-717.</dd>
<dt>3.</dt>
<dd>
<span class="Bold">Morris RB, Cronnelly R, Miller RD, Stanski DR, Fahey MR: </span>Pharmacokinetics of edrophonium and neostigmine when antagonizing d- tubocurarine <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> in man. Anesthesiology 1981;54:399-402.</dd>
<dt>4.</dt>
<dd>
<span class="Bold">Morris RB, Cronnelly R, Miller RD, Stanski DR, Fahey MR: </span>Pharmacokinetics of edrophonium in anephric and renal transplant patients. Br J Anaesth 1981;53:1311-1313.</dd>
<dt>5.</dt>
<dd>
<span class="Bold">Fisher DM, Cronnelly R, Sharma M, Miller RD: </span>Clinical pharmacology of edrophonium in infants and children. Anesthesiology 1984; 61:428-433.</dd>
<dt>6.</dt>
<dd>
<span class="Bold">Silverberg PA, Matteo RS, Ornstein E, Young WL, Diaz J: </span>Pharmacokinetics and pharmacodynamics of edrophonium in the elderly. Anesth Analg 1986;65:S142.</dd>
<dt>7.</dt>
<dd>
<span class="Bold">Virtanen R, Kanto J, Iisalo E, Iisalo EU, Salo M, Sjovall S: </span>Pharmacokinetic studies on atropine with special reference to age. Acta Anaesthesiol Scand 1982;26:297-300.</dd>
<dt>8.</dt>
<dd>
<span class="Bold">Back DJ, Calvey TN: </span>Excretion of <span class="Sup">14</span>C-edrophonium and its metabolites in bile: role of the liver cell and the peribiliary vascular plexus. Br J Pharmacol., 1972; 44:534.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_be9c9bfe-5083-4baa-a063-afc140b813bc"></a><a name="section-13"></a><p></p>
<p class="First">Enlon-Plus is a registered trademark of Mylan Teoranta.</p>
<p>Manufactured for: <br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Akorn Inc.</span><br>Lake Forest, IL 60045 U.S.A.</p>
<p>BEPOON<br>Rev. 01/13</p>
<p>REVISED JANUARY 2013<br>MI:ENLOPS:R2</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_8720b736-ba51-4bd5-8d32-eed6aa110f8d"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mL Ampule</h1>
<p class="First"><span class="Bold">NDC 67457-192-05</span></p>
<p><span class="Bold">Enlon-Plus<span class="Sup">®</span></span><br>(edrophonium chloride, USP and<br>atropine sulfate, USP) injection</p>
<p><span class="Bold">10 mg/mL edrophonium chloride</span><br><span class="Bold">0.14 mg/mL atropine sulfate</span></p>
<p><span class="Bold">For Intravenous Use</span></p>
<p><span class="Bold">Rx only</span>     <span class="Bold">10 x 5 mL Single-Dose Ampules</span></p>
<p><span class="Bold">Each mL contains:</span> edrophonium chloride, USP 10 mg; atropine sulfate, USP 0.14 mg; sodium citrate (dihydrate), USP; citric acid (anhydrous), USP; sodium sulfite, ACS 2.0 mg; water for injection, USP qs 1 mL.</p>
<p>Enlon-Plus is a registered trademark of Mylan Teoranta</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying prescribing<br>information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>MI:192:10C:R2</p>
<p>Made in U.S.A.</p>
<p>BEPAAC Rev. 01/13</p>
<p><span class="Bold">Mylan.com</span></p>
<div class="Figure">
<a name="id720"></a><img alt="Enlon-Plus (edrophonium choloride, USP and atropine sulfate, USP) injection 10 mg/ mL edrophonium chloride 0.14 mg/ mL atropine sulfate Carton Labels" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=358336e5-3628-49ec-9134-6ec8c4ea733a&amp;name=91173b67-b234-4b01-8598-5e14b8ef2fe4-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ENLON PLUS 		
					</strong><br><span class="contentTableReg">edrophonium chloride and atropine sulfate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-192</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Edrophonium Chloride</strong> (Edrophonium) </td>
<td class="formItem">Edrophonium Chloride</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Atropine Sulfate</strong> (Atropine) </td>
<td class="formItem">Atropine Sulfate</td>
<td class="formItem">0.14 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Sulfite</strong></td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Citrate</strong></td>
<td class="formItem">13.2 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Citric Acid Monohydrate</strong></td>
<td class="formItem">8.2 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-192-05</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-192-00</td>
<td class="formItem">5 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019678</td>
<td class="formItem">11/06/1991</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Institutional LLC
							(790384502)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>91173b67-b234-4b01-8598-5e14b8ef2fe4</div>
<div>Set id: 358336e5-3628-49ec-9134-6ec8c4ea733a</div>
<div>Version: 7</div>
<div>Effective Time: 20130131</div>
</div>
</div> <div class="DistributorName">Mylan Institutional LLC</div></p>
</body></html>
